To identify a new class of blood nanoparticles that may improve early diagnosis of Alzheimer’s disease.
Approach:
Study Design: The study analyzed blood and brain samples from 26 individuals with confirmed Alzheimer’s disease or no evidence of the disease, comparing three classes of extracellular particles.
Particle Identification: Researchers focused on a new type of particle called 'SECmeres' that carry brain-derived RNA signatures.
Laboratory Workflow: Introduced a method called SECrifuge to isolate SECmeres efficiently.
Key Findings:
SECmeres consistently distinguished Alzheimer’s disease from cognitively normal controls.
SECmeres contained distinct brain-derived RNA markers such as L1CAM, neurogranin, and others.
The SECrifuge method is more reproducible and cost-effective than traditional ultracentrifugation.
Interpretation:
Limitations:
The study cohort was small and primarily consisted of White participants.
Samples were collected post-mortem, limiting applicability to living patients.
Further research is needed with larger, more diverse cohorts and living patients.
A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.
